Axsome Therapeutics, Inc. (AXSM) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the Axiom Therapeutics fourth quarter and full year 2025 earnings conference call. My name is Kevin, and I'll be your operator for today's call. At this time, all participants are in listen-only mode. Later, there will be a question-and-answer session, and instructions will be given at that time. Please note, this call is being recorded. I would now like to hand the floor to Ashley Dong, Director of Investor Relations. Ashley, please go ahead. Thank you. Good morning, and thank you all for joining Accent's fourth quarter and full year 2025 earnings conference call. With us today are Dr. Ariel Tabuto, our Chief Executive Officer, Nick Pizzi, our Chief Financial Officer, and Ari Maizel, our Chief Commercial Officer, who will begin our call with prepared remarks. Mark Jacobson, our Chief Operating Officer, and Hunter Murdoch, our General Counsel, will also be available for Q&A. Before we begin, I encourage everyone to visit the investor section of our website to find the press release and presentation for today's call. Please note that today's discussion includes forward-looking statements regarding our financial performance, commercial strategy, and operational plans, including research, development, and regulatory activities. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that may cause actual results to differ materially. Please refer to our SEC filings, including our quarterly and annual reports, for description of these and other risks. We are cautioned not to rely on these forward-looking statements, which are made only as of today, and the company disclaims any obligation to update such statements. And with that, I'll hand it over to Ariel. Thank you, Ashley, and good morn...